Vaxcyte to Release Phase 3 Trial Data for 31-Valent Pneumococcal Vaccine
Vaxcyte will host a live webcast Oct. 5 to share topline results from OPUS-1, the pivotal adult trial of its VAX-31 pneumococcal vaccine candidate.
Vaxcyte, Inc. (Nasdaq: PCVX) announced it will present topline data from its OPUS-1 adult pivotal Phase 3 clinical trial on October 5, 2026, at 8:00 a.m. ET via a public webcast and conference call. The San Carlos, California-based company describes itself as a clinical-stage vaccine innovation firm.
The OPUS-1 trial is evaluating the safety, tolerability, and immunogenicity of VAX-31, Vaxcyte's 31-valent pneumococcal conjugate vaccine candidate. The breadth of VAX-31's coverage — targeting 31 distinct pneumococcal serotypes — positions it as one of the most expansive candidates in its class if trial results prove favorable.
Read more Monteverde & Associates Probes Four Mergers Over Shareholder Rights →
The vaccine is designed to prevent invasive pneumococcal disease and pneumococcal pneumonia in adults, conditions that collectively account for significant morbidity and mortality, particularly among older populations. Pneumococcal conjugate vaccines have been a cornerstone of infectious disease prevention, and competitive pressure in the space has intensified as manufacturers race to expand serotype coverage beyond currently approved products.
Topline Phase 3 readouts are closely watched by investors and public health officials alike, as they represent the first large-scale signal of whether a candidate is likely to clear regulatory hurdles. Vaxcyte has not pre-released any data, and the October 5 event represents the first public disclosure of OPUS-1 results.
Continue reading at GlobeNewswire - Industry News on Financial Services.
